{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:26:06Z","timestamp":1762521966410},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40259-016-0206-1","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:04:28Z","timestamp":1483020268000},"page":"37-49","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review"],"prefix":"10.1007","volume":"31","author":[{"given":"Massimo","family":"Radin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,29]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1592\/phco.30.4.339","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339\u201353. doi:10.1592\/phco.30.4.339.","journal-title":"Pharmacotherapy"},{"key":"206_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000233234","volume":"219","author":"N Bansback","year":"2009","unstructured":"Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209\u201318. doi:10.1159\/000233234.","journal-title":"Dermatology"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14712598.2014.858695","volume":"14","author":"T Billiet","year":"2014","unstructured":"Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-\u03b1 for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75\u2013101. doi:10.1517\/14712598.2014.858695.","journal-title":"Expert Opin Biol Ther"},{"key":"206_CR4","first-page":"1","volume":"50","author":"M Changes","year":"1998","unstructured":"Changes M. Infliximab (Remicade) anti-TNF. Interactions. 1998;50:1\u201325.","journal-title":"Interactions"},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009;58:492\u2013500. doi:10.1136\/gut.2008.155812.","journal-title":"Gut"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337:1029\u201335. doi:10.1056\/NEJM199710093371502.","journal-title":"N Engl J Med"},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19\u201331. doi:10.1053\/j.gastro.2003.10.047.","journal-title":"Gastroenterology"},{"key":"206_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"A Kuek","year":"2007","unstructured":"Kuek A, Hazleman BL, Ost\u00f6r AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83:251\u201360. doi:10.1136\/pgmj.2006.052688.","journal-title":"Postgrad Med J"},{"key":"206_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12325-012-0035-7","volume":"29","author":"Y Liu","year":"2012","unstructured":"Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn\u2019s disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29:620\u201334. doi:10.1007\/s12325-012-0035-7.","journal-title":"Adv Ther"},{"key":"206_CR10","unstructured":"CHMP. Remsima, INN: infliximab. 2013."},{"key":"206_CR11","unstructured":"CHMP. Inflectra; INN: infliximab. 2013."},{"key":"206_CR12","unstructured":"Press Announcements\u2014FDA approves Inflectra, a biosimilar to Remicade."},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613\u201320. doi:10.1136\/annrheumdis-2012-203090.","journal-title":"Ann Rheum Dis"},{"key":"206_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605\u201312. doi:10.1136\/annrheumdis-2012-203091.","journal-title":"Ann Rheum Dis"},{"key":"206_CR15","doi-asserted-by":"publisher","unstructured":"Smits LJT, Derikx LAAP, de Jong DJ, et al. Clinical outcomes following a switch from Remicade\u00ae to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. doi:10.1093\/ecco-jcc\/jjw087.","DOI":"10.1093\/ecco-jcc\/jjw087"},{"key":"206_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","volume":"15","author":"K Farkas","year":"2015","unstructured":"Farkas K, Rutka M, B\u00e1lint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis\u2014experiences from a single center. Expert Opin Biol Ther. 2015;15:1257\u201362. doi:10.1517\/14712598.2015.1064893.","journal-title":"Expert Opin Biol Ther"},{"key":"206_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","volume":"9","author":"SH Park","year":"2015","unstructured":"Park SH, Kim Y-H, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9:35\u201344. doi:10.1586\/17474124.2015.1091309.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"206_CR18","doi-asserted-by":"publisher","unstructured":"Jung YS, Park D Il, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015. doi:10.1111\/jgh.12997.","DOI":"10.1111\/jgh.12997"},{"key":"206_CR19","doi-asserted-by":"publisher","unstructured":"Gecse KB, Lov\u00e1sz BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn\u2019s Colitis. 2015. doi:10.1093\/ecco-jcc\/jjv220.","DOI":"10.1093\/ecco-jcc\/jjv220"},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","volume":"60","author":"YS Kang","year":"2015","unstructured":"Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951\u20136. doi:10.1007\/s10620-014-3392-z.","journal-title":"Dig Dis Sci"},{"key":"206_CR21","doi-asserted-by":"publisher","unstructured":"Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. doi:10.1093\/ecco-jcc\/jjw085.","DOI":"10.1093\/ecco-jcc\/jjw085"},{"key":"206_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365521.2016.1149883","volume":"5521","author":"R Keil","year":"2016","unstructured":"Keil R, Wasserbauer M, Z\u00e1dorov\u00e1 Z, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis. Scand J Gastroenterol. 2016;5521:1\u20137. doi:10.3109\/00365521.2016.1149883.","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"206_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","volume":"9","author":"J Jahnsen","year":"2015","unstructured":"Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45\u201352. doi:10.1586\/17474124.2015.1091308.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","volume":"10","author":"J Sieczkowska","year":"2016","unstructured":"Sieczkowska J, Jarz\u0119bicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10:127\u201332. doi:10.1093\/ecco-jcc\/jjv233.","journal-title":"Preliminary observations. J Crohns Colitis"},{"key":"206_CR25","doi-asserted-by":"publisher","unstructured":"Buer LCT, Moum BA, Cvancarova M, et al. Switching from Remicade\u00ae to Remsima\u00ae is well tolerated and feasible: a prospective, open-label study. J Crohn\u2019s Colitis. 2016. doi:10.1093\/ecco-jcc\/jjw166.","DOI":"10.1093\/ecco-jcc\/jjw166"},{"key":"206_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1974","unstructured":"Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1974;70:439\u201344. doi:10.1016\/S0016-5085(76)80163-1.","journal-title":"Gastroenterology"},{"key":"206_CR27","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jgh.12324","volume":"28","author":"K-M Lee","year":"2013","unstructured":"Lee K-M, Jeen YT, Cho JY, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol. 2013;28:1829\u201333. doi:10.1111\/jgh.12324.","journal-title":"J Gastroenterol Hepatol"},{"key":"206_CR28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u201385. doi:10.1056\/NEJMoa030815.","journal-title":"N Engl J Med"},{"key":"206_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.mpg.0000183350.46795.42","volume":"41","author":"J Hyams","year":"2005","unstructured":"Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416\u201321. doi:10.1097\/01.mpg.0000183350.46795.42.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"206_CR30","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/ajg.2010.143","volume":"105","author":"D Turner","year":"2010","unstructured":"Turner D, Griffiths AM, Walters TD, et al. Appraisal of the Pediatric Crohn\u2019s Disease Activity Index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105:2085\u201392. doi:10.1038\/ajg.2010.143.","journal-title":"Am J Gastroenterol"},{"key":"206_CR31","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ibd.20867","volume":"15","author":"D Turner","year":"2009","unstructured":"Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15:1218\u201323. doi:10.1002\/ibd.20867.","journal-title":"Inflamm Bowel Dis"},{"key":"206_CR32","doi-asserted-by":"crossref","unstructured":"Harvey RF, Bradshaw MJ. Measuring Crohn\u2019s disease activity. Lancet (London, England). 1980;1:1134\u20135.","DOI":"10.1016\/S0140-6736(80)91577-9"},{"key":"206_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29\u201332.","journal-title":"Gut"},{"key":"206_CR34","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376. doi:10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"key":"206_CR35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/gut.2003.018515","volume":"53","author":"T Ljung","year":"2004","unstructured":"Ljung T, Karl\u00e9n P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849\u201353.","journal-title":"Gut"},{"key":"206_CR36","first-page":"829","volume":"62","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Dai C, Liu W. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Hepatogastroenterology. 2015;62:829\u201337.","journal-title":"Hepatogastroenterology"},{"key":"206_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1517\/14740338.2015.1029915","volume":"14","author":"R Khanna","year":"2015","unstructured":"Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opin Drug Saf. 2015;14:987\u201397. doi:10.1517\/14740338.2015.1029915.","journal-title":"Expert Opin Drug Saf"},{"key":"206_CR38","doi-asserted-by":"publisher","unstructured":"Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2016; annrheumdis-2015-208783. doi:10.1136\/annrheumdis-2015-208783.","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"206_CR39","doi-asserted-by":"publisher","unstructured":"Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016;13:annrheumdis-2015-208786. doi:10.1136\/annrheumdis-2015-208786.","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"206_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","volume":"16","author":"H Lee","year":"2014","unstructured":"Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16:22\u20136. doi:10.1208\/s12248-013-9534-y.","journal-title":"AAPS J"},{"key":"206_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138. doi:10.1056\/NEJMoa020888.","journal-title":"N Engl J Med"},{"key":"206_CR42","first-page":"1","volume":"18","author":"J Flood","year":"2009","unstructured":"Flood J. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications. Manag Care. 2009;18:1\u20135.","journal-title":"Manag Care"},{"key":"206_CR43","doi-asserted-by":"publisher","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Ruiz del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016; annrheumdis-2015-208684. doi:10.1136\/annrheumdis-2015-208684.","DOI":"10.1136\/annrheumdis-2015-208684"},{"key":"206_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.155","author":"S Danese","year":"2016","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2016;. doi:10.1038\/nrgastro.2016.155.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-016-0206-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T13:36:26Z","timestamp":1659101786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-016-0206-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s40259-016-0206-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]},"assertion":[{"value":"29 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Radin, S. Sciascia,\u00a0D. Roccatello and\u00a0M. J. Cuadrado declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potential competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}